Abstract
The occurrence of drug resistance in oncology accounts for treatment failure and relapse of diverse tumor types. Cancers contain cells at various stages of differentiation together with a limited number of 'cancer-initiating cells' able to self-renew and divide asymmetrically, driving tumorigenesis. Cancer-initiating cells display a range of self-defense systems that include almost all mechanisms of drug-resistance. Different molecular pathways and markers, identified in this malignant sub-population, are becoming targets for novel compounds and for monoclonal antibodies, which may be combined with conventional drugs. These interventions might eliminate drug-resistant cancer-initiating cells and lead to remission or cure of cancer patients.
| Original language | English |
|---|---|
| Pages (from-to) | 435-442 |
| Number of pages | 8 |
| Journal | Drug Discovery Today |
| Volume | 17 |
| Issue number | 9-10 |
| DOIs | |
| Publication status | Published - May 2012 |
Fingerprint
ASJC Scopus subject areas
- Drug Discovery
- Pharmacology
Cite this
Targeting cancer-initiating cell drug-resistance : A Sroadmap to a new-generation of cancer therapies? / Alama, Angela; Orengo, Anna Maria; Ferrini, Silvano; Gangemi, Rosaria.
In: Drug Discovery Today, Vol. 17, No. 9-10, 05.2012, p. 435-442.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Targeting cancer-initiating cell drug-resistance
T2 - A Sroadmap to a new-generation of cancer therapies?
AU - Alama, Angela
AU - Orengo, Anna Maria
AU - Ferrini, Silvano
AU - Gangemi, Rosaria
PY - 2012/5
Y1 - 2012/5
N2 - The occurrence of drug resistance in oncology accounts for treatment failure and relapse of diverse tumor types. Cancers contain cells at various stages of differentiation together with a limited number of 'cancer-initiating cells' able to self-renew and divide asymmetrically, driving tumorigenesis. Cancer-initiating cells display a range of self-defense systems that include almost all mechanisms of drug-resistance. Different molecular pathways and markers, identified in this malignant sub-population, are becoming targets for novel compounds and for monoclonal antibodies, which may be combined with conventional drugs. These interventions might eliminate drug-resistant cancer-initiating cells and lead to remission or cure of cancer patients.
AB - The occurrence of drug resistance in oncology accounts for treatment failure and relapse of diverse tumor types. Cancers contain cells at various stages of differentiation together with a limited number of 'cancer-initiating cells' able to self-renew and divide asymmetrically, driving tumorigenesis. Cancer-initiating cells display a range of self-defense systems that include almost all mechanisms of drug-resistance. Different molecular pathways and markers, identified in this malignant sub-population, are becoming targets for novel compounds and for monoclonal antibodies, which may be combined with conventional drugs. These interventions might eliminate drug-resistant cancer-initiating cells and lead to remission or cure of cancer patients.
UR - http://www.scopus.com/inward/record.url?scp=84857144607&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84857144607&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2011.02.005
DO - 10.1016/j.drudis.2011.02.005
M3 - Article
C2 - 21315830
AN - SCOPUS:84857144607
VL - 17
SP - 435
EP - 442
JO - Drug Discovery Today
JF - Drug Discovery Today
SN - 1359-6446
IS - 9-10
ER -